🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 155 of 857 · Phase 3 first, then by program name

  1. Raloxifene - Usual

    Lxo Ireland Designated Activity Company

    Breast Cancer

    phase 3 small molecule active

    1 trial

  2. Raltegravir

    United Therapeutics Europe Ltd

    Human Immunodeficiency Virus

    phase 3 small molecule completed

    1 trial

  3. Raludotatug Deruxtecan

    Merck Sharp and Dohme

    Gastrointestinal Cancers

    phase 3 small molecule active

    1 trial

  4. Ramelteon

    Takeda

    Balance

    phase 3 small molecule completed

    1 trial

  5. Ramelteon

    Takeda

    Transient Insomnia

    phase 3 small molecule completed

    1 trial

  6. Ramelteon

    Takeda

    Sleep Initiation and Maintenance Disorders

    phase 3 small molecule completed

    2 trials

  7. Ramelteon SL

    Takeda

    Bipolar Disorder

    phase 3 small molecule terminated

    1 trial

  8. Ramelteon SL

    Takeda

    Acute Depressive Episode

    phase 3 small molecule terminated

    1 trial

  9. Ramelteon SL (Dose 1)

    Takeda

    Bipolar Disorder

    phase 3 small molecule terminated

    1 trial

  10. Ramelteon and Placebo (9 possible combinations total)

    Takeda

    Chronic Insomnia

    phase 3 small molecule completed

    1 trial

  11. Ramosetron

    Astellas Pharma Inc

    Vomiting

    phase 3 small molecule completed

    1 trial

  12. Ramucirumab

    Eli Lilly and Company

    Urothelial Carcinoma

    phase 3 small molecule completed

    1 trial

  13. Randomized control trial comparison between intra-articular infiltrations of PRP, MFAT, and PRP-MFAT in the treatment of symptomatic knee osteoarthritis.

    ISTA Pharma Limited

    knee osteoarthritis

    phase 3 other active

    1 trial

  14. Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 other active

    1 trial

  15. Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors

    Sanofi-aventis Healthcare Pty Ltd

    Non-small cell lung cancer metastatic

    phase 3 other active

    1 trial

  16. Ranibizumab

    Novartis Pharmaceuticals

    Retinopathy of Prematurity (ROP)

    phase 3 small molecule completed

    1 trial

  17. Ranibizumab

    Hoffmann-La Roche

    Neovascular Age-related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  18. Ranibizumab

    Novartis Pharmaceuticals

    Retinopathy of Prematurity

    phase 3 small molecule completed

    1 trial

  19. Ranibizumab

    Regeneron UK Limited

    Macular Degeneration

    phase 3 small molecule completed

    2 trials

  20. Ranibizumab 0.5 mg

    Novartis Pharmaceuticals

    Central Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  21. Rapastinel

    Allergan Pharmaceuticals International Limited

    Depressive Disorder, Major

    phase 3 small molecule terminated

    1 trial

  22. Rasagiline

    Teva Pharma GmbH

    Progressive Supranuclear Palsy

    phase 3 small molecule terminated

    1 trial

  23. Ravulizumab

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  24. Ravulizumab

    Alexion Europe SAS

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 mab completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources